Source:http://linkedlifedata.com/resource/pubmed/id/10064126
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
1999-5-4
|
pubmed:abstractText |
We have studied the clinical usefulness of urinary bone resorption markers in postmenopausal women with symptomatic osteoporosis. The study design is a randomised double-blind placebo controlled study, in which the subjects were daily treated for 24 months either with a hormone analogue (2.5 mg Livial, generic name Tibolone, Organon, Amsterdam, Holland) plus 800 mg calcium (n = 14, age 63+/-5 years, range 52-68 years), or with placebo plus 800 mg calcium (n = 19, age 66+/-7 years, range 50-75 years). The laboratory methods for urinary bone resorption markers were enzyme immunoassays (EIA) for urinary pyridoline (PYD) and deoxypyridoline crosslinks (DPD), and for cross-linked N-telopeptides of Type I Collagen (NTx), and an HPLC assay for urinary hydroxyproline (HOP). All the urine assay results were calculated per mmol creatinine. All the resorption markers decreased during the two-year study period in both groups. The Z scores (discriminating power, i.e. ability of the different tests to distinguish the hormone treated subjects from the placebo treated subjects) for HOP and PYD were rather low: 0.06-1.52 for HOP and 0.68-1.47 for PYD. The differences between the two treatment groups were statistically significant for DPD at 12 and 24 months of treatment (P = 0.0471 and P = 0.0466, respectively), the Z scores ranging 0.45-1.90. NTx showed the most prominent decrease from the beginning of the study especially in the hormone treatment group: the differences between the two treatment groups were statistically highly significant for NTx already at 6 months of treatment (P = 0.0015), and the Z scores remained high ranging 2.11-3.82 throughout the two-year study period. Dual X-ray absorptiometry (DXA) of the lumbar spine and femoral neck did not show statistically significant differences between the two treatment groups throughout the two-year study period. After 2 years there was, however, a significant increase in bone density both in the spine (+ 6.6%, P = 0.0002) and in the femoral neck (+ 3.4%, P = 0.0389) in the women with hormone treatment. In the control group a significant increase (+ 5.1%, P = 0.0012) in the spine, whereas a non-significant decrease (-1.5%, n.s.) in the femoral neck was observed. We suggest that measurement of urinary cross-linked peptides derived from Type I collagen (NTx and DPD) might be a useful biochemical method of observing the positive clinical effect (i.e. reduction in bone resorption) following hormone replacement therapy in postmenopausal fracture patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anabolic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxyproline,
http://linkedlifedata.com/resource/pubmed/chemical/Norpregnenes,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Placebos,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/collagen type I trimeric...,
http://linkedlifedata.com/resource/pubmed/chemical/tibolone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0009-8981
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
279
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
145-54
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10064126-Aged,
pubmed-meshheading:10064126-Anabolic Agents,
pubmed-meshheading:10064126-Biological Markers,
pubmed-meshheading:10064126-Bone Resorption,
pubmed-meshheading:10064126-Calcium,
pubmed-meshheading:10064126-Collagen,
pubmed-meshheading:10064126-Collagen Type I,
pubmed-meshheading:10064126-Double-Blind Method,
pubmed-meshheading:10064126-Female,
pubmed-meshheading:10064126-Humans,
pubmed-meshheading:10064126-Hydroxyproline,
pubmed-meshheading:10064126-Immunoenzyme Techniques,
pubmed-meshheading:10064126-Middle Aged,
pubmed-meshheading:10064126-Norpregnenes,
pubmed-meshheading:10064126-Osteoporosis, Postmenopausal,
pubmed-meshheading:10064126-Peptides,
pubmed-meshheading:10064126-Placebos,
pubmed-meshheading:10064126-Pyridines
|
pubmed:year |
1999
|
pubmed:articleTitle |
Urinary bone resorption markers in monitoring treatment of symptomatic osteoporosis.
|
pubmed:affiliation |
Department of Clinical Chemistry, Kuopio University Hospital, Finland. markku.parviainen@finhost.fi
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|